Sandra and Edward Meyer Cancer Center

Dr. Dan Landau has received a Lotus Award from the Pershing Square Foundation for research aimed at uncovering new immunotherapy targets in ovarian cancer.

Prostate-targeted, engineered nanoparticles made of amorphous silica are effective in killing prostate tumors directly while enhancing anti-tumor immunity, according to a preclinical study led by investigators at Weill Cornell Medicine and the Cornell David A. Duffield College of Engineering. 

A carefully designed metal-free carbon monoxide prodrug—an inactive compound that is converted into its active form in the body—may help prevent some of the deadliest forms of cancer from spreading, according to researchers at Weill Cornell Medicine.

A new technology allows scientists to map, in single cells, the DNA binding sites of transcription factors and other regulatory proteins that control gene activity, according to a study led by investigators at Weill Cornell Medicine and the New York Genome Center.

The ASCERTAIN V clinical trial, led by Weill Cornell Medicine researchers, demonstrated that an all-oral drug combination for older patients with acute myeloid leukemia (AML) is an effective alternative to the current standard, which requires repeated hospital or office visits for intravenous treatment. 

Weill Cornell Medicine received a five-year, $5 million grant from the National Cancer Institute, part of the National Institutes of Health, to develop innovative support strategies for an understudied group of cancer patients: adolescents and young adults (AYAs).

According to a new preclinical study by Weill Cornell Medicine and MD Anderson Cancer Center investigators, colorectal tumors often find multiple ways to survive treatment, including additional genetic mutations and activation of cellular pathways typically associated with inflammation and regeneration. 

Activated immune cells secrete tiny capsules bearing DNA that can enter other immune and tumor cells to stimulate the body’s defense systems, according to a study led by investigators at Weill Cornell Medicine. 

Nerve fibers within melanomas can slow the growth of these tumors, according to a study led by Weill Cornell Medicine investigators. 

The 45th annual Vincent du Vigneaud Memorial Research Symposium, a student-organized event that has become central to the Weill Cornell Graduate School of Medical Sciences experience, had a record number of 153 abstracts submitted this year, including posters and eight oral presentations.

For the first time, Weill Cornell Medicine researchers have demonstrated that Hodgkin lymphoma cancer cells from patient samples are immune cells stuck in an “identity crisis.” 

A team of Weill Cornell Medicine investigators is working to cross-train the next generation of cancer researchers in cancer biology and the use of artificial intelligence tools for research.

Temporarily disabling a protein complex that organizes DNA into loops inside the cell’s nucleus drastically disrupted the three-dimensional structure of the genome, but surprisingly most genes continued to function as usual, Weill Cornell Medicine researchers found. 

We sat down with Dr. Jia Ruan to learn more about her clinical research and how she thinks it will help lymphoma patients.

A $1 million Research Scholar Grant from the American Cancer Society will help a multi-institution team led by Dr. Bishoy Faltas, associate professor of medicine at Weill Cornell Medicine, to develop new therapy combinations for hard-to-treat urinary tract cancers.

Six researchers from Weill Cornell Medicine have received Young Investigator Awards from the Prostate Cancer Foundation. 

An enigmatic type of circulating tumor cell called a dual-positive cell is associated with shorter survival time in patients with advanced breast cancer, according to a study led by investigators at Weill Cornell Medicine. 

A gene called FOXJ1 may drive resistance to taxane chemotherapy during treatment for advanced prostate cancer, according to a new study led by investigators at Weill Cornell Medicine and Beth Israel Deaconess Medical Center. 

Dr. Ekta Khurana, an associate professor of systems and computational biomedicine at Weill Cornell Medicine, has received a two-year, $1 million Challenge Award from the Prostate Cancer Foundation to work with researchers from Weill Cornell Medicine and Memorial Sloan Kettering Cancer Center on an AI-based method for early detection of treatment-resistant prostate tumor subtypes.

Awards, honors and achievements for the month of February.